Resources from the same session
Hereditary Predisposition to Pancreatic Cancer: Whom and How To Screen and What to Look For?
Presenter: Judith Balmaña, Spain
Session: Session II: Cancer of the Pancreas
Resources:
Slides
Management of Pre-Malignant Pancreatic Lesions
Presenter: Pascal Hammel, France
Session: Session II: Cancer of the Pancreas
Resources:
Slides
Clinical and molecular features of patients with KRAS wild-type pancreatic adenocarcinoma
Presenter: Imen Ben-Ammar, France
Session: Session II: Cancer of the Pancreas
Resources:
Slides
Debate: Molecular Changes in Pancreatic Ductal Adenocarcinoma: NGS in All Patients With PDAC - PRO
Presenter: Thomas Seufferlein, Germany
Session: Session II: Cancer of the Pancreas
Resources:
Slides
Debate: Molecular Changes in Pancreatic Ductal Adenocarcinoma: NGS in All Patients With PDAC - CON
Presenter: Jordan Berlin, United States
Session: Session II: Cancer of the Pancreas
Resources:
Slides
Comparison of resected vs. non-resected patients with unresectable locally advanced pancreatic cancer (LAPC) receiving P-32 microparticles with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy in the PanCO study
Presenter: Paul Ross, United Kingdom
Session: Session II: Cancer of the Pancreas
Resources:
Slides
Cases With Panel Discussion: Resectable, Borderline Resectable, and Unresectable Pancreatic Cancer
Presenter: Eric Van Cutsem, Belgium; Margaret Tempero, United States; Oliver Strobel, Austria; Karin Haustermans, Belgium; Gerald Prager, Austria; Maria Antonietta Bali, Belgium
Session: Session II: Cancer of the Pancreas
Resources:
Slides
Are We Making Progress in Targeting the Microenvironment and Immune System in PDAC?
Presenter: Eileen O'Reilly, United States
Session: Session II: Cancer of the Pancreas
Resources:
Slides